Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Other Non Operating Income (2016 - 2026)

Aytu Biopharma has reported Other Non Operating Income over the past 11 years, most recently at $190000.0 for Q4 2025.

  • Quarterly Other Non Operating Income rose 35.71% to $190000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, up 383.17% year-over-year, with the annual reading at -$594000.0 for FY2024, 422.83% down from the prior year.
  • Other Non Operating Income was $190000.0 for Q4 2025 at Aytu Biopharma, down from $3.8 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $3.8 million in Q3 2025 and troughed at -$5.9 million in Q3 2023.
  • The 5-year median for Other Non Operating Income is $140000.0 (2024), against an average of $344526.3.
  • Year-over-year, Other Non Operating Income soared 5577.5% in 2022 and then plummeted 17257.14% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$257000.0 in 2021, then surged by 645.91% to $1.4 million in 2022, then tumbled by 93.16% to $96000.0 in 2023, then surged by 45.83% to $140000.0 in 2024, then soared by 35.71% to $190000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Non Operating Income are $190000.0 (Q4 2025), $3.8 million (Q3 2025), and $1.3 million (Q2 2025).